ELABPMGC Holdings Inc.

NorthStrive Biosciences, a subsidiary of PMGC Holdings (NASDAQ:ELAB), is taking another step toward advancing its engineered probiotic platform by initiating an independent flow cytometry (FACS) characterization program for EL-22, its lead therapeutic candidate designed to help preserve muscle during weight-loss treatment, including the rapidly expanding use of GLP-1 receptor agonists.

Three emerging biotechnology companies, Can-Fite BioPharma (NYSEAMERICAN:CANF), NeOnc Technologies (NASDAQ:NTHI), and PMGC Holdings (NASDAQ:ELAB) through its NorthStrive Biosciences subsidiary, are pursuing a distinct therapeutic strategy, the common theme is execution. Clinical data, regulatory milestones, AI-assisted discovery platforms, and expanding development pipelines are creating a steady stream of catalysts that investors will be watching closely during the second half of 2026.

PMGC Holdings acquired a controlling stake of 76% in an Arizona-based company that serves in aerospace, space, defense, semiconductor, and medical-device markets.

PMGC secured an agreement to draw additional funds beyond the $40 million financing for the next 24 months.

Shares of PMGC Holdings Inc. (NASDAQ: ELAB) are trading higher on Monday after the company announced one of its subsidiaries, NorthStrive Biosciences, transferred a key project to a U.S.-based...

PMGC Holdings Inc. (NASDAQ: ELAB) stock drops Friday as traders react to share dilution concerns following a volatile week for the defense tech firm.read more...

A wave of innovation across AI robotics, biotechnology, advanced materials, and clean energy is reshaping the small-cap landscape. $ONCO, $KBLB, $ELAB, $GLMD, $TURB, $GAME

AGA Precision expands defense role with new Tier 1 aerospace contract under parent PMGC Holdings (NASDAQ: ELAB).read more...

PMGC had entered into a share sale agreement with Streeterville last September.